Kenya’s Omaera Pharmaceuticals plans to spend Sh3.1 billion in the next three years for purchase and exclusive sale of the cancer and HIV drug, Lodonal, across East Africa.
In an agreement signed with the US-based specialty drugmaker, Immune Theraupetics, Omaera agreed to distribute and market the drug known for its non-toxic therapy for the management of cancer, HIV, autoimmune diseases and other inflammatory conditions.
